Infect Chemother.  2024 Mar;56(1):1-12. 10.3947/ic.2024.0011.

Epidemiology and Disease Burden of Respiratory Syncytial Virus Infection in Adults

• Kim T
• Choi SH

• KMID: 2554973
• DOI: http://doi.org/10.3947/ic.2024.0011

Abstract

Respiratory syncytial virus (RSV) constitutes a significant cause of respiratory illness and mortality among older adults, a demographic that is expanding with considerable impact on healthcare systems worldwide. The actual burden of RSV in this population may still be underestimated, owing to factors such as low awareness and suboptimal diagnostic sensitivity in adults, the lack of robust RSV surveillance systems, and the infrequent use of diagnostic testing. Recent advancements in respiratory virus detection have spurred further exploration into appropriate preventive and therapeutic strategies. The recent approval of two vaccines highlights the critical need for the precise estimation of the RSV disease burden to optimize the effectiveness and cost-efficiency of immunization programs. This narrative review aimed to summarize the existing knowledge of the RSV burden in adults with a particular focus on older adults, incorporating data from Korea. Overall, current estimates indicate that the annual RSV attack rate in the general adult population ranges from 1 - 7%, increasing to approximately 4 - 10% among elderly and high-risk groups. The in-hospital mortality rate can be estimated to be around 7 - 10%, rising up to 40% among intensive care unit-admitted patients. To elucidate RSV’s disease burden, further continuing research, including population-based studies, is necessary.

Keyword

Respiratory syncytial virus; RSV vaccine; Elderly; Disease burden; Epidemiology